Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.

@article{Qiu2019TargetedDO,
  title={Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.},
  author={Qiujun Qiu and Cong Li and Yanzhi Song and Tao Shi and Xiang Luo and Hongxia Zhang and Ling Hu and Xinyang Yan and Huangliang Zheng and Mengyang Liu and Mingqi Liu and Min Liu and Shuaishuai Yang and Xinrong Liu and Guoliang Chen and Yihui Deng},
  journal={Acta biomaterialia},
  year={2019},
  volume={92},
  pages={
          184-195
        }
}
Ibrutinib (IBR), an irreversible Bruton's tyrosine kinase (BTK) inhibitor, is expected to be a potent therapeutic modality, given that BTK is overexpressed in tumor-associated macrophages (TAMs) and participates in promoting tumor progression, angiogenesis, and immunosuppression. However, rapid clearance in vivo and low tumor accumulation have rendered effective uptake of IBR by TAMs challenge. Herein, we designed and synthesized a sialic acid (SA)-stearic acid conjugate modified on the surface… CONTINUE READING
BETA
1
Twitter Mention